Why is NeoGenomics stock dropping on Tuesday?

Oct 6, 2026, 1:57 PM ETResultsRead the original at Benzinga

Neutral

NeoGenomics reported 28% growth in next-generation sequencing testing, but still expects a net loss and kept its 2026 sales forecast unchanged. The planned CEO handoff and analysts’ concerns offer no clear sign of a changed outlook.

NEO · NeoGenomics Inc.

AI read · Neutral

The AI's read

The growth in a key testing area is encouraging, but the update gives no sign that NeoGenomics changed its total sales forecast or ended its expected losses. Analysts also cited slow growth and past execution problems. The planned CEO handoff has no stated business result yet.

Get alerts for NEO

Follow NeoGenomics Inc. (NEO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NEO

Free on the App Store and Google Play, or on the web.